Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: Diatide

This article was originally published in The Gray Sheet

Executive Summary

Diatide: Planning to use proceeds of a proposed initial public offering to fund "research and product development, preclinical studies and clinical trials, to repay bank debt and for general corporate purposes." The radiopharmaceutical manufacturer filed a registration statement with SEC for 2.5 mil. shares of common stock for an anticipated price of between $10-$12 per share. The offering reflects an anticipated 6-for-10 stock split, after which the company would have approximately 10.5 mil. shares outstanding. Underwriters Dillon, Read & Co. and Oppenheimer & Co. have been granted an option to purchase up to 375,000 additional shares to cover over-allotments...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005863

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel